Drugs / CNTX-4975-05
last change Jun 2020 re-read 2 minutes ago

CNTX-4975-05

also known as capsaicin · trans-capsaicin
Developed for
osteoarthritis, knee
Investigated by
Centrexion Therapeutics

Trials 4 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT03576508 Jun → Sep 2018 osteoarthritis, knee Centrexion Therapeutics Completed No outcome recorded
Phase 33 trials
Phase 3 NCT03661996 Sep 2018 → Oct 2019 osteoarthritis, knee Centrexion Therapeutics Completed No outcome recorded
Phase 3 NCT03660943 Sep 2018 → Jun 2020 osteoarthritis, knee Centrexion Therapeutics Completed No outcome recorded
Phase 3 NCT03429049 Jan 2018 → Nov 2019 osteoarthritis, knee Centrexion Therapeutics Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03472677 Background Mar → Jul 2018 osteoarthritis, knee Centrexion Therapeutics Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as CNTX-4975-05 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03576508
4

NCT03660943

NCT03429049

NCT03472677

NCT03661996

Known as capsaicin “CNTX-4975-05 (capsaicin)” NCT03429049
Known as trans-capsaicin “CNTX-4975-05 (trans-capsaicin)” NCT03472677
Route Other “intra-articular injection” NCT03429049